Exhibits heterocyclic compound binding activity and histamine receptor activity. Involved in cellular response to histamine and negative regulation of arachidonic acid secretion. Localizes to membrane. Biomarker of transient cerebral ischemia. Orthologous to human HRH2 (histamine receptor H2); PARTICIPATES IN cimetidine pharmacodynamics pathway; cimetidine pharmacokinetics pathway; esomeprazole pharmacodynamics pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; ammonium chloride.
4-methylhistamine binds to and results in increased activity of HRH2 protein, [4-methylhistamine binds to and results in increased activity of HRH2 protein] which affects the expression of CD14 protein
[Cimetidine binds to and results in decreased activity of HRH2 protein] results in decreased susceptibility to [Histamine co-treated with [Oxygen deficiency co-treated with Oxygen]] more ...
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]], HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]
Dimaprit binds to and results in increased activity of HRH2 protein, HRH2 protein promotes the reaction [Dimaprit results in increased expression of IL6 mRNA]
Dimaprit binds to and results in increased activity of HRH2 protein, Ranitidine inhibits the reaction [Dimaprit binds to and results in increased activity of HRH2 protein]
[Cimetidine binds to and results in decreased activity of HRH2 protein] results in decreased susceptibility to [Histamine co-treated with [Oxygen deficiency co-treated with Oxygen]]
[Cimetidine binds to and results in decreased activity of HRH2 protein] results in decreased susceptibility to [Histamine co-treated with [Oxygen deficiency co-treated with Oxygen]] more ...
[[thioperamide results in increased abundance of Histamine] which results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine more ...
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]] more ...
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]] more ...
HRH2 protein promotes the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]], HRH2 protein promotes the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]]
HRH2 protein affects the reaction [Histamine inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]] more ...
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]], HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]
[[thioperamide results in increased abundance of Histamine] which results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine, Cimetidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine]
[[thioperamide results in increased abundance of Histamine] which results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine more ...
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
